Biogen Idec MA Inc. develops, manufactures, and markets novel human therapeutic products. The company focuses on developing pharmaceutical products in the areas of neurology, dermatology, and rheumatology. The company’s products include AVONEX, which is used for the treatment of relapsing multiple sclerosis; and AMEVIVE that is used for the treatment of adult patients with plaque psoriasis. Biogen Idec MA Inc. was formerly known as Biogen Inc. and changed the name to Biogen Idec MA Inc. in November 2003. The company was founded in 1978 and is based in Weston, Massachusetts. As of November 12, 2003, Biogen Idec MA Inc. operates as a subsidiary of Biogen Idec Inc.
133 Boston Post Road
Weston, MA 02493
Founded in 1978
Sangamo BioSciences, Inc. Enters into Global Research, Development and Commercialization Collaboration and License Agreement with Biogen Idec MA Inc
Jan 9 14
On January 8, 2014, Sangamo BioSciences Inc. entered into a Global Research, Development and Commercialization Collaboration and License Agreement with Biogen Idec MA Inc., a wholly-owned subsidiary of Biogen Idec Inc., pursuant to which Sangamo and Biogen will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo's DNA-binding technology (ZFP) for hemoglobinopathies, including beta thalassemia (BT) and sickle cell disease (SCD). Under the Agreement, Sangamo and Biogen will jointly conduct two research programs: the BT program and the SCD program. In the BT program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP therapeutic developed under the Agreement for the treatment of BT. In the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (IND) application for ZFP therapeutics intended to treat SCD. Under both programs, Biogen is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the Agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any licensed product to treat BT and SCD developed under the Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities. Moreover, Sangamo and Biogen agreed to form a joint steering committee, consisting of an equal number of representatives of Sangamo and Biogen, to oversee the research programs. Under the Agreement, Sangamo will receive an upfront license fee of $20.0 million. Biogen will reimburse Sangamo for its costs incurred in connection with research and development activities conducted by Sangamo. In addition, Sangamo is eligible to receive development milestone payments upon the achievement of specified regulatory, clinical development and commercialization milestones. The total amount of potential regulatory, clinical development, commercialization, and sales milestone payments, assuming the achievement of all specified milestones in the Agreement and no applicable adjustments, is $293.8 million, including Phase 1 milestone payments of $7.5 million for each BT and SCD program. In addition, Biogen agrees to pay Sangamo incremental royalties for each licensed product that are tiered double-digit percentage of annual net sales of such product.